Novel Treatment Strategies for Multiple Sclerosis: S1P-Based Therapeutics and the Role of Combination Therapy

http://academiccme.com/wp-content/uploads/2018/11/iStock-697998588-wpcf_400x400.jpg

Course Information

Therapautic Area: Neurology
Format(s): Webcast
Credit(s): 1.0 AMA PRA Category 1 Credit™ 1.0 CNE contact hour
Activity Dates: November 23, 2018 - November 22, 2019

 

Program Overview

This continuing education activity will focus on treatment strategies for patients with multiple sclerosis, utilizing S1P-based therapeutics and combination therapy. Four expert faculty will review new and emerging clinical trial data of S1P-based therapeutics. The faculty will also discuss the data and rationale for utilizing combination therapeutics in managing patients with multiple sclerosis. A review of how to utilize the health care team and shared-decision making to achieve improved outcomes in MS patients will be discussed. Upon completion of this educational activity, clinicians will become better acquainted with treatment strategies utilizing S1P-based therapeutics and combination therapy when treating patients with multiple sclerosis.

Target Audience

Neurologist, primary care physicians, internists and advanced practice providers, including NPs and PAs, responsible for the diagnosis, treatment or management of patients with multiple sclerosis.

Learning Objectives

  1. Analyze the most current clinical trial data for newer S1P-based therapeutics
  1. Discuss the data and rationale for utilizing combination therapeutics in managing patients with multiple sclerosis
  1. Utilize the health care team and shared-decision making to achieve improved outcomes

Faculty

Lublin HeadshotFred D. Lublin, MD
Saunders Family Professor of Neurology
Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, NY

 

 

bar_or_amitAmit Bar-Or, MD
Presidential Endowed Professor
Department of Neurology
Director, Center for Neuroinflammation and Experimental Neurotherapeutics
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

 

Freedmand headshotMark S. Freedman, MD
Professor of Medicine
University of Ottawa
Senior Scientist, Ottawa Hospital Research Institute
Ottawa, Ontario, Canada

 

Markowitz HeadshotClyde Markowitz, MD
Director, MS Center
Associate Professor, Department of Neurology
University of Pennsylvania, Perelman School of Medicine
Philadelphia, PA

 

 

 

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:

Faculty Relationship Identified With:
Fred D. Lublin, MD Consultant/Advisor: Abbvie; Acorda; Actelion; Apitope; Atara Biotherapeutics; Bayer HealthCare; Biogen; Brainstorm Cell Therapeutics; EMD Serono; Forward Pharma; GW Pharma; Innate Immunotherapeutics; Jazz Pharmaceuticals; Mapi Pharma; Medday; MedImmune; Novartis Pharmaceuticals Corp; Orion Biotechnology; Polpharma; Roche/Genentech; Receptos/Celgene; Regeneron; Sanofi/Genzyme; Teva; TG TherapeuticsGrant/Research Support: Actelion; Novartis Pharmaceuticals Corp; NMSS; Sanofi; Teva Neuroscience; Transparency Life Sciences
Amit Bar-Or, MD Consultant/Advisor: Actelion; Atara Biotherapeutic; Biogen Idec; Celgene/Receptos; Genentech/Roche; MAPI; Medimmune; Merck/EMD Serono; Novartis, Sanofi-GenzymeGrant/Research Support: Novartis; Genentech
Mark S. Freedman, MD Consultant/Advisor: Actelion; BayerHealthcare; BiogenIdec; Chugai; Clene Nanomedicine; EMD Canada; Genzyme; Hoffman La-Roche; MedDay; Merck Serono; Novartis Pharmaceuticals Corp; Sanofi-Aventis; Teva Canada InnovationGrant/Research Support: Genzyme Canada

Speaker’s Bureau: Sanofi-Genzyme

Clyde Markowitz, MD Consultant/Advisor: Actelion; Bayer AG; Biogen; Celgene, EMD Serono, Inc.; Genentech/Roche; Genzyme/Sanofi; Novartis Pharmaceuticals Corporation; Teva Pharmaceutical

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Boring; Chelsey Benedek and Kim Cheramie, MSN, RN-BC hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission (ANCC) on Accreditation. AcademicCME’s ANCC provider number is P0491.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour.

Financial Support

This activity has been supported by an independent educational grant from Actelion, a Janssen Pharmaceutical Company.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Actelion, a Janssen Pharmaceutical Company do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

CE Inquiries/Special Needs

For all CME inquiries or special needs, please contact admin@academiccme.com.

BUTTON

 


Provided by: AcademicCME-web